ReviewJournal of hepatocellular carcinoma2023
Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma.
Review in Journal of hepatocellular carcinoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.Journal of advanced research · 2026Article
- Anticarcinogenic effects of miR-199a-loaded gold nanoparticles on hepatocellular carcinoma: in vitro study.Scientific reports · 2026Article
- Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer.Frontiers in oncology · 2026Article
- Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma.Recent patents on biotechnology · 2026Article
- Effect of the Evidence-Based and Multidisciplinary Pain Management Program in Patients After Laparoscopic Hepatectomy: A Quasi-Experimental Study.Journal of pain research · 2026Article
- Unveiling the cytotoxicity of Red SeaPharmaceutical biology · 2025Article
- Unveiling the Cytotoxicity Potential of Nanoemulsion ofPharmaceuticals (Basel, Switzerland) · 2025Article
- The role of FOXA1 and miR-212-3p in molecular modulation of doxorubicin resistance in liver cancer.Medical oncology (Northwood, London, England) · 2025Article
- Hepatitis C in North Africa: A Comprehensive Review of Epidemiology, Genotypic Diversity, and Hepatocellular Carcinoma.Advances in virology · 2025Review
- Integrating molecular, biochemical, and immunohistochemical features as predictors of hepatocellular carcinoma drug response using machine-learning algorithms.Frontiers in molecular biosciences · 2024Article
- Construction of Pain Management Strategies After Hepatectomy: Evidence Summary and Delphi Study.Journal of pain research · 2024Article
- Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs).Journal of hepatocellular carcinoma · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
40 authors at 11 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from cancer. The prevalence of this pathology, which has been on the rise in the last 30 years, has been predicted to continue increasing. HCC is the most common cause of cancer-related morbidity and mortality in Egypt and is also the most common cancer in males. Chronic liver diseases, including chronic hepatitis C, which is a primary health concern in Egypt, are considered major risk factors for HCC. However, HCC surveillance is recommended for patients with chronic hepatitis B virus (HBV) and liver cirrhosis; those above 40 with HBV but without cirrhosis; individuals with hepatitis D co-infection or a family history of HCC; and Nonalcoholic fatty liver disease (NAFLD) patients exhibiting significant fibrosis or cirrhosis. Several international guidelines aid physicians in the management of HCC. However, the availability and cost of diagnostic modalities and treatment options vary from one country to another. Therefore, the current guidelines aim to standardize the management of HCC in Egypt. The recommendations presented in this report represent the current management strategy at HCC treatment centers in Egypt. Recommendations were developed by an expert panel consisting of hepatologists, oncologists, gastroenterologists, surgeons, pathologists, and radiologists working under the umbrella of the Egyptian Society of Liver Cancer. The recommendations, which are based on the currently available local diagnostic aids and treatments in the country, include recommendations for future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.